Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX07 + serplulimab + gemcitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
HLX07 + serplulimab + gemcitabine + cisplatin is an investigational combination regimen developed by Shanghai Henlius Biotech for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). The regimen includes HLX07, a humanized anti-EGFR monoclonal antibody engineered for high affinity and low immunogenicity; serplulimab (HLX10), a recombinant humanized anti-PD-1 monoclonal antibody; and a chemotherapy backbone of gemcitabine and cisplatin. By combining targeted EGFR inhibition, immune checkpoint blockade, and cytotoxic chemotherapy, the regimen aims to provide a synergistic anti-tumor effect. It is currently being evaluated in a Phase 2 clinical trial (HLX07-NPC201) where it has shown preliminary efficacy and a manageable safety profile.
- Brand names
- HANSIZHUANG
- Other names
- HLX07 + HLX10 + gemcitabine + cisplatin
02
Targets
Beyond the preview
Go deeper on HLX07 + serplulimab + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX07 + serplulimab + gemcitabine + cisplatin.